Misplaced Pages

NNZ-2591

Clinical data
Other names	Cyclo(L-glycyl-L-2-allylproline)
Legal status
Legal status	Investigational
Identifiers
IUPAC name (8aR)-8a-Prop-2-enyl-3,6,7,8-tetrahydro-2H-pyrrolopyrazine-1,4-dione
CAS Number	847952-38-9
PubChem CID	11735696
DrugBank	DB15601
ChemSpider	9910403
UNII	2T1HU6069S
ChEMBL	ChEMBL4802144
Chemical and physical data
Formula	C10H14N2O2
Molar mass	194.234 g·mol
3D model (JSmol)	Interactive image
SMILES C=CC12CCCN1C(=O)CNC2=O
InChI InChI=1S/C10H14N2O2/c1-2-4-10-5-3-6-12(10)8(13)7-11-9(10)14/h2H,1,3-7H2,(H,11,14)/t10-/m0/s1 Key:WVKCGUOWPZAROG-JTQLQIEISA-N

NNZ-2591 is a synthetic analog of cyclic glycine-proline and experimental drug developed for Angelman syndrome, Phelan-McDermid syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome.

References

1. Markati, Theodora; Duis, Jessica; Servais, Laurent (3 July 2021). "Therapies in preclinical and clinical development for Angelman syndrome". Expert Opinion on Investigational Drugs. 30 (7): 709–720. doi:10.1080/13543784.2021.1939674.
2. Heussler, Helen S. (March 2021). "Emerging Therapies and challenges for individuals with Angelman syndrome". Current Opinion in Psychiatry. 34 (2): 123–128. doi:10.1097/YCO.0000000000000674. ISSN 0951-7367. S2CID 230663523.
3. "An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) (PWS-001) NCT05879614". clinicaltrials.gov. Retrieved 6 December 2023.

• Experimental drugs
• Diketopiperazines